Title
A Whole-Genome RNA Interference Screen Reveals a Role for Spry2 in Insulin Transcription and the Unfolded Protein Response.

Permalink
https://escholarship.org/uc/item/6js6r6p4

Journal
Diabetes, 66(6)

ISSN
0012-1797

Authors
Pappalardo, Zachary
Gambhir Chopra, Deeksha
Hennings, Thomas G
et al.

Publication Date
2017-06-01

DOI
10.2337/db16-0962

Peer reviewed
A Whole-Genome RNA Interference Screen Reveals a Role for Spry2 in Insulin Transcription and the Unfolded Protein Response

Zachary Pappalardo,1 Deeksha Gambhir Chopra,1 Thomas G. Hennings,1,2 Hunter Richards,1 Justin Choe,1 Katherine Yang,1 Luc Baeyens,1 Kenny Ang,3 Steven Chen,3 Michelle Arkin,3 Michael S. German,1,4 Michael T. McManus,1,5 and Gregory M. Ku1,4

Diabetes 2017;66:1703–1712 | https://doi.org/10.2337/db16-0962

Insulin production by the pancreatic β-cell is required for normal glucose homeostasis. While key transcription factors that bind to the insulin promoter are known, relatively little is known about the upstream regulators of insulin transcription. Using a whole-genome RNA interference screen, we uncovered 26 novel regulators of insulin transcription that regulate diverse processes including oxidative phosphorylation, vesicle traffic, and the unfolded protein response (UPR). We focused on Spry2—a gene implicated in human type 2 diabetes by genome-wide association studies but without a clear connection to glucose homeostasis. We showed that Spry2 is a novel UPR target and its upregulation is dependent on PERK. Knockdown of Spry2 resulted in reduced expression of Serca2, reduced endoplasmic reticulum calcium levels, and induction of the UPR. Spry2 deletion in the adult mouse β-cell caused hyperglycemia and hypoinsulinemia. Our study greatly expands the compendium of insulin promoter regulators and demonstrates an overlap between Spry2 and human diabetes.

Worldwide, 354 million people have diabetes, and this is projected to increase to 592 million by the year 2035 (1). The majority of this rise will be in type 2 diabetes, although the incidence of type 1 diabetes also continues to rise (2,3). The pathophysiological common ground of diabetes is β-cell dysfunction and loss. Genome-wide association studies of patients with type 2 diabetes have identified approximately eighty risk loci, many of which are located near genes that would be predicted to affect β-cell function (reviewed by Morris [4]). However, only a few of the identified single nucleotide polymorphisms (SNPs) have been experimentally verified to work through the genes to which they have been assigned. We hypothesized that augmenting current genome-wide association studies results with unbiased screens for the genes that control normal β-cell function would reveal novel targets for future diabetes therapeutics and generate a more complete picture of the genes involved in the pathogenesis of human diabetes.

We performed a whole-genome RNA interference (RNAi) screen for regulators of the human insulin promoter. We identified novel regulators of insulin production including a type 2 diabetes locus, Spry2 (5–7). Spry2 is known to negatively regulate growth factor signaling, but its link to diabetes is not clear. We discovered a novel role for Spry2 in the unfolded protein response (UPR) and established it as a UPR target. Our study provides a blueprint for functionally annotating the β-cell insulin production pathway and reveals a novel mechanism linking Spry2 to human diabetes.

RESEARCH DESIGN AND METHODS

Cells and RNAi Screen
MIN6 cells were a gift from Dr. J. Miyazaki (Osaka University). The screening MIN6 cell line, containing a lentivirally

Received 7 August 2016 and accepted 16 February 2017.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-0962/-/DC1.
© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
See accompanying article, p. 1467.
delivered copy of the human insulin promoter driving EGFP and a distinct integrated copy of the rous sarcoma virus (RSV) promoter driving mCherry, was previously described (8). A total of 1.25 pmol of each small interfering RNA (siRNA) from the Qiagen Whole Genome Mouse siRNA library version 1.0 was placed individually into wells of 384-well plates. Totals of 0.05 μL of RNAiMax (Life Technologies) and 9.95 μL of Opti-MEM (Life Technologies) followed by 10,000 reporter MIN6 cells in 40 μL of growth media (DMEM high glucose, 10% FBS, penicillin, streptomycin) were added to each well. Five days after transfection, fluorescence was read using an Analyst HT (Molecular Devices). GFP fluorescence was divided by mCherry fluorescence. Wells with mCherry fluorescence 1.5 SD below the mean of that plate were removed because of presumed cellular toxicity. Scores were median two-way polished to remove datasets because of presumed cellu lar toxic ity. Scores were median two-way polished to remove db because of presumed cellu lar toxic ity.

Quantitative RT-PCR
Total RNA was prepared with TRIzol Reagent (Life Technologies) followed by DNA digestion with TURBO DNase (Ambion). Oligo-dT– and random hexamer–primed cDNA was synthesized with SuperScript III (Life Technologies). For TaqMan primers, the delta-delta CT method was used using the average CT of 18S–glucuronidase, cyclophilin, and TBP as reference genes. For SYBR Green primers, data were normalized to β-actin. Primer sequences are listed in Supplementary Table 4.

mRNA-Seq
A single RNA isolation from the screening cell line was used to generate a polyA-primed mRNA-Seq library as previously described, except Cufflinks 2.0.2 was used for the fragments per kilobase of transcript per million mapped reads (FPKM) determination (9,10). Reads have been deposited in the National Center for Biotechnology Information Sequence Read Archive (SAMN06250888).

Gene Ontology Term Enrichment
Database for Annotation, Visualization and Integrated Discovery v6.7 was used to find enriched gene ontology (GO) terms (11).

Mice
Spry2 floxed mice were a gift from Dr. O. Klein (University of California, San Francisco). Mouse insulin promoter–CreERT (MP1-CreERT) mice were a gift from Dr. N. Tamarina (University of Chicago). Mice received three subcutaneous 2-mg tamoxifen injections (Sigma-Aldrich) at 6 weeks of age; each injection was separated by a day. Intrapitoneal glucose tolerance testing was performed at 12 weeks: 2 g/kg glucose was injected into the peritoneal space after a 6-h fast, and blood glucose was monitored with a FreeStyle Lite Glucometer (Abbott). Glucose tolerance P values between the three genotypes were calculated using a one-way ANOVA with repeated measures followed by pairwise comparisons corrected with the Benjamini-Hochberg method for multiple testing. The glucose area under the curve above fasting was measured using the trapezoidal method. Insulin tolerance tests were performed at 14 weeks: after a 6-h fast, 0.1 mU/gram body weight of regular insulin was injected into the peritoneal space. Plasma insulin levels were measured at 15 weeks: after a 16-h fast and after a 2 g/kg intraperitoneal glucose injection. Islets were isolated as previously described (12). RNA was harvested with TRIzol 1 day after isolation.

Western Blots
Cells were lysed in buffer containing the following: 50 mmol/L TrisHCl pH 6.7, 150 mmol/L NaCl, 1% Triton X-100, cComplete Protease Inhibitor Cocktail (Roche), Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich), and Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich). The following antibodies were used: anti-Wfs1 (11558–1-AP; Proteintech), phospho-PERK (3179; Cell Signaling), phospho-Eif2α (3398; Cell Signaling), total Eif2α (9722S; Cell Signaling), total PERK (31925; Cell Signaling), GAPDH (G8795; Sigma-Aldrich), Spry2 (ab50317; Abcam), and Serca2 (sc-8095; Santa Cruz Biotechnology). Ilet protein samples were isolated from the TRIzol Reagent organic phase after RNA isolation as described in the protocol, except the pellet was resuspended in 5 mol/L urea in 0.5% SDS.

D1ER Calcium Measurements
Unmodified MIN6 cells were infected with a lentivirus expressing endoplasmic reticulum (ER)-targeted fluorescent cameleon D1ER. If indicated, the cells were transfected with the indicated siRNAs and rested for 5 days prior to analysis. For measurement of ER cells low in calcium, the cells were trypsinized and resuspended in complete media. Flow cytometry was performed using an Attune Cytometer (Life Technologies) using VL2 and VL1 as the fluorescence resonance energy transfer (FRET) emission channel and the CFP (donor) channel, respectively. VL2 was divided by VL1 to calculate the FRET signal. The FRET low population was defined as those having >33% reduction in the FRET signal compared with the geometric mean of the population. FRET low was typically 5–8% of the cell population for the control siRNA transfection.

siRNAs
Anti-luciferase siRNA, AllStars Negative Control siRNA, and Negative Control siRNA were obtained from Qiagen.

Annexin V Staining
Parental MIN6 cells were stained with Annexin V Alexa Fluor 488 & Propidium Iodide (Life Technologies) and analyzed by flow cytometry (Attune; Life Technologies). The percentage of total events that were annexin V positive and propidium iodide negative is shown. For percent cell death, MIN6 cells were trypsinized and the percentage of events in the live gate determined by forward and side scatter was subtracted from 100%.
Statistics
Unless otherwise specified, P values were calculated by two-tailed Student t test and corrected for false discovery using the Benjamini-Hochberg method. For quantitation of Western blot bands (phospho-PERK, phospho-Eif2α, Spry2 induction by UPR inducers, Spry2 or Wfs1 knockdown), the log-transformed ratio of the experimental condition to the control condition was used for a one-sample Student t test.

RESULTS
Whole-Genome RNAi Screen for Regulators of the Insulin Promoter
To elucidate genes that alter insulin transcription, we previously generated a MIN6 mouse insulinoma clonal cell line that harbors an EGFP reporter driven by the proximal 362 bases of the human insulin promoter. To avoid selecting hits that affect general transcription, this line was engineered to constitutively express a control mCherry reporter driven by the RSV promoter (8). This reporter cell line was used in a high-throughput RNAi screen using a commercial library containing 75,366 unique siRNAs targeting ~22,000 mouse genes with 3–4 unique siRNAs per gene. Each siRNA was individually reverse transfected into the reporter cell line in 384-well plates. Five days after transfection, the ratio of GFP to mCherry fluorescence was measured (Fig. 1A). The plate-based assay performance metric Z’ typically ranged from 0.6–0.8 (0.5 is considered acceptable; Supplementary Fig. 1A) (13). Gene-level P values for positive regulators of insulin expression (reduced GFP/mCherry) were

---

**Figure 1**—Whole-genome RNAi screen reveals novel regulators of the insulin promoter. 
A: Screen schematic: MIN6 cells expressing EGFP under control of the insulin promoter and mCherry (mCh) under control of the RSV promoter are transfected with siRNAs in 384-well plates, and GFP and mCherry are read out by a plate reader. 
B: –log(p) value for positive regulator genes screened as determined by RSA. 
C: Enriched GO term categories with enrichment scores [–log(p)]. 
D: GFP/mCherry fluorescence for siRNAs during secondary screening normalized (norm) to control anti-luciferase siRNA. Each point represents the GFP/mCherry fluorescence compared with control with SEM. siRNAs are ordered by RSA rank for positive regulators (right cluster), randomly selected from all siRNAs (center cluster), or ordered by RSA rank for negative regulators (left cluster). 
E: Criteria used for selection of siRNAs for secondary screening and overall confirmation rates. IPA, Ingenuity Pathway Analysis.
determined using the redundant siRNA analysis (RSA), where P values are assigned based on the number and strength of siRNAs to that gene (14).

A portion of the screen was repeated with an alternative lipid transfection reagent to ensure results were not specific to the transfection reagent used. Normalized scores for each siRNA were well correlated (Supplementary Fig. 1B), and gene-level P values for positive regulators of insulin transcription were also well correlated (Supplementary Fig. 1C). To reduce off-target effects, we did not further consider siRNAs targeting genes that were not expressed using mRNA-Seq of the screening cell line (Supplementary Table 1). As would be expected, the fraction of hits that were not expressed in the screening cell line increased as more inferior hits were considered (Supplementary Fig. 1D).

When ranked based on low GFP/mCherry (i.e., specific suppression of insulin expression), the key β-cell transcription factors, Glis3, Pdx1, and NeuroD1, were ranked 3rd, 17th, and 29th, respectively (Fig. 1B), providing strong validation for the screen. Wfs1, a known regulator of both insulin production and insulin secretion, was also identified. GO terms involving mitochondria, DNA transcription, vesicular transport, and cytoskeleton were significantly enriched among the top 300 genes that, when knocked down, reduced GFP/mCherry (Fig. 1C).

To validate the primary screen, we retested the top 40 siRNAs targeting putative positive regulators, selecting the top 2–3 performing siRNAs for each gene by GFP/mCherry reduction. These siRNAs were transfected into the screening cell line in biological triplicate, and GFP and mCherry were measured. Of the top 40 siRNAs targeting putative positive regulators, 36 (90%) reduced GFP/mCherry compared with a control siRNA during retesting. Of 50 random siRNAs selected from the library, only one showed a statistically significant reduction in GFP/mCherry (Fig. 1D). We then selected additional siRNAs for retesting based on β-cell expression, interconnectivity (based on GO term enrichment), and published data for a specific role in β-cell function (Fig. 1E). In total, 141 siRNAs targeting positive regulators were tested in the screening assay with RSA ranks up to 6,313. A total of 112/141 (79%) showed a statistically significant reduction in GFP/mCherry compared with a control siRNA (Fig. 1F and Supplementary Table 2).

As GFP/mCherry fluorescence is a surrogate for insulin promoter activity, siRNAs were tested for their ability to reduce endogenous, unspliced insulin mRNA, as this has a shorter half-life than mature insulin message (15,16). We used a quantitative RT-PCR (qRT-PCR) assay for preIns1 mRNA, as we found that this was more sensitive to Pdx1, Glis3, and NeuroD1 knockdown than preIns2 mRNA (data not shown). A total of 78/108 (72%) siRNAs reduced preIns1 mRNA. We considered genes with two siRNAs showing reduced preIns1 mRNA as high-confidence hits. We found 29 such genes, 26 of which did not have a known role in insulin promoter activity. An additional 15 genes had one of two siRNAs reduce insulin mRNA levels (Fig. 2A). With the exception of three genes without a known human ortholog, all of our validated hits are expressed in human islets at reads per kilobase of transcript per million mapped reads (RPKM) >0.1, suggesting that they could play a similar role in insulin production in human β-cells (Supplementary Table 3) (17). Although the screen was not optimized to detect increases in GFP/mCherry, when the siRNAs were ranked according to increased GFP/mCherry (targeting putative negative regulators), the top 40 siRNAs did tend to subtly increase GFP/mCherry during retesting (Fig. 1D). However, a low rate of these siRNAs increased preIns1 mRNA (data not shown), so we focused on the positive regulators.

To begin to validate our screen in vivo, we examined global knockout (ko) mice of Gpr75, one of the G-protein–coupled receptor hits in the screen. We found that Gpr75 ko mice were modestly hyperglycemic compared with their wild-type (wt) or heterozygous littermates (Supplementary Fig. 2A and B), despite being more insulin sensitive and having lower body weight (Supplementary Fig. 2C and D). Plasma insulin levels were lower before and after a glucose challenge in Gpr75 ko mice as compared with their wt littermates (Supplementary Fig. 2E). Finally, insulin secretion in vitro was also blunted in islets from Gpr75 ko mice (Supplementary Fig. 2F). These data show that our in vitro whole-genome RNAi screen was capable of detecting in vivo regulators of β-cell function.

**Spry2 Is a Novel Regulator of β-Cell Insulin Transcription**

Among the other novel hits, we were particularly interested in Spry2 because it has been identified in multiple studies as a type 2 diabetes risk locus (5,7). We first returned to the original confirmation qRT-PCR for preIns1. Of the two Spry2 siRNAs initially retested, only Spry2.4 statistically significantly reduced preIns1 mRNA; Spry2.6 had a weaker effect and a false discovery rate (FDR)-adjusted P value of 0.13 after three biological replicates (Fig. 2A and Supplementary Table 2). Therefore, we tested all three siRNAs targeting Spry2 that were identified as hits in the primary screen. After nine biological replicates, all three independent siRNAs to Spry2 statistically significantly reduced preIns1 mRNA levels in MIN6 cells after FDR correction (Fig. 2B). All three siRNAs reduced Spry2 mRNA levels (Supplementary Fig. 3).

**Spry2 Is a UPR Target**

In many cell types, Spry2 negatively regulates Ras-MAPK signaling (18). Since MAPK signaling is thought to positively regulate insulin transcription, we sought another mechanism for Spry2’s positive influence on insulin production (19). We hypothesized that Spry2 might play a role in the UPR, as dominant negative Spry2 expression in the mouse lens has been reported to increase ER stress (20). Furthermore, SPRY2 was induced in human islets treated with palmitate, which induces ER stress (21).

We first asked whether Spry2 is induced by established chemical UPR inducers. Exposure of MIN6 cells to the sarcoplasmic/endoplasmic reticulum calcium ATPase (Serca) inhibitor thapsigargin increased Spry2 mRNA
and protein expression (Fig. 3A and B). The degree of upregulation was similar to that of Wfs1 mRNA, a gene known to be upregulated by ER stress (22,23). The N-linked glycosylation inhibitor and ER stress inducer tunicamycin also increased Spry2 mRNA and protein (Supplementary Fig. 4A and B). Mouse embryonic fibroblasts (MEFs) also upregulated Spry2 mRNA in response to thapsigargin (Fig. 3C) or tunicamycin (Fig. 3D). However, MEFs deficient in PERK did not upregulate Spry2 mRNA in response to thapsigargin or tunicamycin. Finally, since knockdown of Wfs1 is known to increase ER stress in β-cells, we asked whether knockdown of Wfs1 might also increase Spry2 expression in MIN6 cells (24,25). Multiple siRNAs targeting Wfs1 increased Spry2 mRNA and Spry2 protein expression in the absence of any other ER stress inducer (Fig. 3E and F). Notably, these Wfs1 siRNAs were effective in knockdown of Wfs1 mRNA (Supplementary Fig. 4C) and Wfs1 protein (Supplementary Fig. 4D) and in reducing prelns1 mRNA (Supplementary Fig. 4E).

**Knockdown of Spry2 Triggers the UPR**

Next, we hypothesized that Spry2 could play a role in regulating the UPR. Knockdown of Spry2 by multiple independent siRNAs resulted in increased levels of the UPR markers CHOP and spliced Xbp1 (Fig. 4A and B). Bip expression did not increase after either Spry2 or Wfs1 knockdown (data not shown). To further confirm activation of the UPR, we examined the activation of the ER stress sensor PERK and its target Eif2α after siRNA knockdown of Spry2 or Wfs1. Both phospho-PERK and phospho-Eif2α levels increased after either Spry2 or Wfs1 knockdown (Fig. 4C–E). ATF4 and ATF6 levels did not change after Spry2 knockdown (Supplementary Fig. 5). Since ER stress in β-cells can trigger apoptosis, we measured the frequency of annexin V+ cells after Spry2 knockdown. Indeed, knockdown of Spry2 increased the fraction of annexin V+ cells (Fig. 4F).

**Spry2 Affects Serca2 Expression and ER Calcium Levels**

Since PERK activation can be triggered by low levels of ER calcium, we measured ER calcium levels using the D1ER cameleon reporter by flow cytometry (26,27). Treatment of D1ER-expressing MIN6 cells with EDTA and ionomycin resulted in an ~60% increase in the number of cells with low levels of FRET, confirming our ability to monitor ER calcium concentrations with D1ER (Supplementary Fig. 6A and B). When D1ER MIN6 cells were transfected with anti-Wfs1 siRNAs, there was a 40% increase in ER calcium–low cells, in line with what has been previously reported (26). Spry2 knockdown by two independent siRNAs also increased the fraction of cells with low levels of ER calcium by 25% (Fig. 5A).

Decreased ER calcium could be caused by increased activity of IP3 receptors. However, neither IP1 levels (a breakdown product of IP3) nor expression of PLCγ1, a producer of IP3 that can be regulated by Spry2, changed after Spry2 knockdown (Supplementary Fig. 6C and D). Phosphorylated PLCγ1 was not detectable with or without Spry2 knockdown (data not shown). Therefore, we examined levels of Serca2 after Spry2 knockdown. Serca2 protein levels were reduced by 50% after Spry2 knockdown (Fig. 5B and C), while mRNA levels were not changed (Fig. 5D), suggesting posttranscriptional control of Serca2 protein by Spry2.
Alleviating ER Stress Rescues Spry2’s Effect on Insulin Production and β-Cell Survival

Since ER stress is known to impact insulin promoter activity, we asked whether amelioration of ER stress could restore insulin production in Spry2 knockdown cells. Treatment with tauroursodeoxycholic acid (TUDCA) was able to rescue the reduced insulin mRNA seen after Spry2 knockdown (Fig. 5E). Furthermore, TUDCA treatment was able to partially rescue increased β-cell death in MIN6 cells after Spry2 knockdown (Fig. 5F).

β-Cell–Specific Deletion of Spry2 Results in Hyperglycemia and Hypoinsulinemia

To demonstrate a role for Spry2 in vivo, we crossed a conditional allele of Spry2 to MIP1-CreERT mice (28,29) (Fig. 6A). Since we were unable to identify a Spry2 antibody suitable for immunohistochemistry, we used droplet digital PCR to measure ko efficiency from islet genomic DNA. Compared with Spry2 wt/wt MIP1-CreERT mice injected with tamoxifen (Spry2 wt), there was a 50% reduction in Spry2 islet genomic DNA in Spry2 fl/fl MIP1-CreERT mice injected with tamoxifen (Spry2 β-ko) (Supplementary Fig. 7A). The heterozygous Spry2 mice (Spry2 β-het) showed an intermediate degree of reduction. As ~70% of the cells from islets are expected to be β-cells, we estimate that the recombination efficiency was approximately 70%. As Spry2 mRNA is present at approximately twofold higher levels in the mouse α-cell than in the mouse β-cell, we observed a modest but significant reduction in Spry2 from total islet mRNA of these animals (Supplementary Fig. 7B) (30). Protein levels of Spry2 were reduced in Spry2 β-ko islets compared with Spry2 β-het islets (Supplementary Fig. 7C and D).

We asked whether loss of Spry2 could result in changes in glycemia. After glucose challenge, the Spry2 β-ko mice were statistically significantly hyperglycemic relative to either Spry2 wt or Spry2 β-het mice (Fig. 6B and C). Spry2 β-ko mice also had lower plasma insulin levels 15 min after glucose injection (Fig. 6D), while their insulin tolerances and weights were not different (Supplementary Fig. 7E and F). Islets from Spry2 β-ko mice had slightly lower levels of mature Ins1/2 mRNA, confirming our findings in MIN6 cells (Fig. 6E).

Despite lower insulin mRNA levels, total pancreatic insulin content normalized to total protein was not reduced...
in the Spry2 β-ko as compared with β-het islets (Supplementary Fig. 7G), and we also did not find any difference in β-cell area in the Spry2 β-ko as compared with the Spry2 β-het mice (Supplementary Fig. 7H). Batch in vitro glucose-stimulated insulin secretion of islets from Spry2 β-het or Spry2 β-ko mice was also not different (Supplementary Fig. 7I).

**DISCUSSION**

We describe the first whole-genome RNAi screen for regulators of the insulin promoter. In terms of absolute insulin mRNA reduction, the strongest hits came from knockdown of the well-known transcription factors Glis3, NeuroD1, and Pdx1—perhaps not surprising since these proteins bind directly to the insulin promoter. Other hits were previously known to positively regulate insulin secretion in the β-cell but not insulin transcription. For example, Gpr142 was known to positively regulate insulin secretion in vivo and in vitro, and we now identify it as a potential regulator of insulin transcription (31,32). Gpr75 positively regulates insulin secretion in cell lines, and our data further these findings by showing that loss of Gpr75 results in impaired insulin secretion in vivo (33). More importantly, these data show that our screen was able to identify regulators of β-cell function that are relevant in vivo. Since most of our hits have no known connection to β-cell function, the study of these novel regulators will greatly expand our understanding of insulin regulation.

On a global level, this unbiased screen highlights several critical pathways required for insulin transcription. Multiple components of the oxidative phosphorylation cascade were identified as positive regulators of
insulin mRNA production (Atp5a1, Atp5j2, Cox6b1, Cox6c, Cox7a2). While oxidative phosphorylation is known to be important in glucose sensing for insulin secretion, our data suggests that it is also important for insulin transcription (34).

ER stress and the UPR were another thematic area identified by the screen. The UPR is known to reduce insulin transcription through multiple mechanisms, including ATF6 and spliced XBP1 (35–37). Besides Wfs1, activation of the UPR likely also explains the hits involved in vesicular trafficking between the ER and the Golgi (Copb1, Gbf1, Sec23b). In fact, mice lacking the small GTPase Sec23b lack professional secretory cells (including β-cells) and have UPR activation in the embryonic pancreas (38).

We chose to focus on Spry2 because a SNP near the gene is associated with type 2 diabetes. We show a novel role for Spry2 in insulin transcription and glucose homeostasis in vivo. Furthermore, we demonstrate that Spry2 is both a target and a negative regulator of the PERK arm of the UPR, suggesting that upregulation of Spry2 may be a part of the homeostatic response to increased ER stress. However, we were unable to detect a change in β-cell area or in in vitro insulin secretion in Spry2 β-ko mice. Since the hyperglycemia of the Spry2 β-ko mice was relatively mild, we might only expect a small reduction in these assays that could be below our limit of detection. Therefore, the defect in the Spry2 β-ko islets could be from reduced mass, reduced insulin secretion, or possibly both.

Our data nonetheless demonstrate an explanation of how a SNP near Spry2 might cause human diabetes—through activation of the β-cell UPR. How could loss of Spry2 activate the UPR? Although Spry1 and Spry2 have been previously shown to bind to and negatively regulate PLCg1 activity in non-β-cells, thereby reducing inositol triphosphate production and calcium efflux from the ER, we did not observe changes in PLCγ1 phosphorylation or increased inositol phosphate production (39). Instead, we found that Spry2 knockdown in β-cells causes reduced Serca2 protein levels, suggesting a possible mechanism by which Spry2 loss might cause reduced ER calcium and the UPR. However, since ER calcium concentrations can also be reduced by high levels of ER stress, it remains possible that Spry2 loss causes ER stress by an alternative mechanism, such as accumulation of ubiquitylated proteins, decreased autophagy, or altered vesicular traffic (20,26,40,41). Future studies will be required to define how Spry2 loss results in activation of the UPR.

In summary, we have performed the first whole-genome RNAi screen in β-cells. We have identified novel and unexpected positive regulators of the insulin promoter and have begun to elucidate how these genes function together to control pancreatic β-cell insulin production. Specifically,
we have demonstrated a novel role for Spry2 in the UPR and in insulin production in β-cells, possibly explaining the association between SNPs near Spry2 and type 2 diabetes susceptibility. Further understanding of the role of Spry2 and the UPR may provide novel therapeutic inroads to understand and treat human diabetes.

Acknowledgments. The authors thank Dr. Feroz Papa (University of California, San Francisco) for useful discussion.

Funding. This work was supported by National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases grants 5R01-DK-021344 (M.S.G.), 5RC1-DK-086290 (M.T.M.), 5K08-DK-087945 and 5R01-DK-107650 (G.M.K.), and P30-DK-087945; National Institute of Mental Health grant U01MH105028 (M.T.M.); the A.P. Giannini Foundation (G.M.K.); and JDRF grant 5-CDA-2014-199-A-N (G.M.K.).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. M.S.G., M.T.M., and G.M.K. conceived of the experiments. Z.P., D.G.C., T.G.H., H.R., J.C., K.Y., L.B., K.A., S.C., M.A., and G.M.K. performed experiments, analyzed data, and reviewed the manuscript. G.M.K. wrote the manuscript. G.M.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in abstract form at the 75th Scientific Sessions of the American Diabetes Association, Boston, MA, 5–9 June 2015.

References
1. International Diabetes Federation. IDF Diabetes Atlas, 7th edition [Internet]. 2015. Available from http://diabetesatlas.org. Accessed 3 August 2016
2. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010;39:481–497
3. Dabelea D, Mayer-Davis EJ, Saydah S, et al.; SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014;311:1778–1786
4. Morris AP. Fine mapping of type 2 diabetes susceptibility loci. Curr Diab Rep 2014;14:549

5. Imamura M, Iwata M, Maegawa H, et al. Genetic variants at CDC123/CAMK1D and SPRY2 are associated with susceptibility to type 2 diabetes in the Japanese population. Diabetologia 2011;54:3071–3077

6. Mahajan A, Go MJ, Zhang W, et al. Diabetics Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in multi-ethnic Samples (T2D-GENES) Consortium. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 2014;46:234–244

7. Shu XO, Long J, Cai Q, et al. Identification of new genetic risk variants for type 2 diabetes. PLoS Genet 2010;6:e1001127

8. Ku GM, Pappalardo Z, Luo CC, German MS, McManus MT. An siRNA screen in pancreatic beta cells reveals a role for Gpr27 in insulin production. PLoS Genet 2012;8:e1002449

9. Ku GM, Kim H, Vaughn IW, et al. Research resource: RNA-Seq reveals unique features of the pancreatic β-cell transcriptome. Mol Endocrinol 2012;26:1783–1792

10. Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012;7:562–578

11. Huang DW, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007;35:W169–W175.

12. Szot GL, Kourdia P, Bluestone JA. Murine pancreatic islet isolation. J Vis Exp 2007;(7):255

13. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biolum Screen 1999;4:67–73

14. König R, Chiang CY, Tu BP, et al. A probability-based approach for the analysis of large-scale RNA screens. Nat Methods 2007;4:847–849

15. Evans-Molina C, Garmey JC, Ketchum R, Brayman KL, Deng S, Mirmira RG. Glucose regulation of insulin gene transcription and pre-mRNA processing in human islets. Diabetes 2007;56:827–835

16. Iype T, Francis J, Garmery JC, et al. Mechanism of insulin gene regulation by the pancreatic transcription factor Pax-4: application of pre-mRNA analysis and chromatin immunoprecipitation to assess formation of functional transcriptional complexes. J Biol Chem 2005;280:16798–16807

17. Ezirik DL, Sammeh M, Boukenenoghe T, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012;8:e1002552

18. Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol 2009;203:191–202

19. Kho S, Grissen SC, Xia Y, Baer RJ, German MS, Cobb MH. Regulation of insulin gene expression by ERK1 and ERK2 in pancreatic beta cells. J Biol Chem 2003;278:32969–32977

20. Reneker LW, Chen H, Overbeek PA. Activation of unfolded protein response in transgenic mouse lenses. Invest Ophthalmol Vis Sci 2011;52:2100–2108

21. Cnop M, Abdulkarim B, Bottu G, et al. RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. Diabetes 2014;63:1978–1993

22. Ueda K, Kawano J, Takeda K, et al. Endoplasmic reticulum stress induces Wfs1 gene expression in pancreatic beta-cells via transcriptional activation. Eur J Endocrinol 2005;153:167–176

23. Fonseca SG, Fukushima M, Lipson KL, et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem 2005;280:39609–39615

24. Riggs AC, Bernal-Mizrachi E, Ohsugi M, et al. Mice conditionally lacking the Woflam gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia 2005;48:2313–2321

25. Yamada T, Ishihara H, Tamura A, et al. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum Mol Genet 2006;15:1600–1609

26. Hara T, Mahadevan J, Kanekura K, Hara M, Lu S, Urano F. Calcium efflux from the endoplasmic reticulum leads to β-cell death. Endocrinology 2014;155:758–768

27. Palmer AE, Jin C, Reed JC, Tsien RY. Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci U S A 2004;101:17404–17409

28. Wickstead B, Brissova M, Yan W, et al. Conditional gene targeting in mouse pancreatic β-Cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 2010;59:3090–3098

29. Shim K, Minowada G, Coling DE, Martin GR. Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell 2009;5:553–564

30. Benner C, van der Meulen T, Cacères E, Tiggy K, Donaldson CJ, Huisings MO. The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 2014;15:620

31. Lin HV, Efanov AM, Fang X, et al. GPR142 controls troposphin-induced insulin and incretin hormone secretion to improve glucose metabolism. PLoS One 2016;11:e0157298

32. Wang J, Carrillo JJ, Lin HV. GPR142 agonists stimulate glucose-dependent insulin secretion via Gq-dependent signaling. PLoS One 2016;11:e0154452

33. Liu B, Hassan Z, Amisten S, et al. The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis. Diabetes 2013;56:2467–2476

34. Prentki M, Matschinsky FM, Madiroju SR. Metabolic signaling in fuel-induced insulin secretion. Cell Metab 2013;18:162–185

35. See HY, Kim YD, Lee KM, et al. Endoplasmic reticulum stress-induced activation of activating transcription factor 6 decreases insulin gene expression via up-regulation of orphan nuclear receptor small heterodimer partner. Endocrinology 2008;149:3832–3841

36. Amyot J, Benterik I, Fontès G, et al. Binding of activating transcription factor 6 to the A5/Core of the rat insulin II gene promoter does not mediate its transcriptional repression. J Mol Endocrinol 2011;47:273–283

37. Allagnat F, Christulia F, Ortis F, et al. Sustained production of spliced X-box binding protein 1 (XBP1) induces pancreatic beta cell dysfunction and apoptosis. Diabetesologia 2010;53:1120–1130

38. Tao J, Zhu M, Wang H, et al. SEC23B is required for the maintenance of murine professional secretory tissues. Proc Natl Acad Sci U S A 2012;109:3090–E2009

39. Akbulut S, Reddi AL, Aggarwal P, et al. Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C. Mol Biol Cell 2010;21:3487–3496

40. Preston AM, Gurisik E, Bartley C, Laybutt DR, Biden TJ. Reduced endoplasmic reticulum (ER)-to-Golgi protein trafficking contributes to ER stress in lipotoxic mouse beta cells by promoting protein overload. Diabetologia 2009;52:2369–2373

41. Bachar-Wikstrom E, Wikstrom JD, Ariav Y, et al. Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes 2013;62:1227–1237